{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=41&state=Michigan",
    "query": {
      "state": "Michigan",
      "city": "Detroit",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 7238,
    "total_pages": 724,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=42&state=Michigan&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=40&state=Michigan&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T23:39:10.702Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06111235",
      "title": "A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Muscle Invasive Bladder Cancer",
        "Urologic Cancer",
        "Bladder Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cretostimogene Grenadenorepvec",
          "type": "DRUG"
        },
        {
          "name": "n-dodecyl-B-D-maltoside",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 367,
      "start_date": "2023-12-14",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 90,
      "location_summary": "Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111235"
    },
    {
      "nct_id": "NCT01627249",
      "title": "Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "2.0 mg intravitreal aflibercept",
          "type": "DRUG"
        },
        {
          "name": "1.25 mg intravitreal bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "0.3 mg intravitreal ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2012-08",
      "completion_date": "2019-04-18",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 90,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627249"
    },
    {
      "nct_id": "NCT00349726",
      "title": "Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature",
        "Retinopathy of Prematurity",
        "Bronchopulmonary Dysplasia (BPD)"
      ],
      "interventions": [
        {
          "name": "Inositol lower volume",
          "type": "DRUG"
        },
        {
          "name": "Inositol higher volume",
          "type": "DRUG"
        },
        {
          "name": "Placebo lower volume",
          "type": "DRUG"
        },
        {
          "name": "Placebo higher volume",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Days",
        "maximum_age": "6 Days",
        "sex": "ALL",
        "summary": "3 Days to 6 Days"
      },
      "enrollment_count": 74,
      "start_date": "2006-06",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 11,
      "location_summary": "New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349726"
    },
    {
      "nct_id": "NCT00720915",
      "title": "D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Discontinue anticoagulant therapy (Negative d-dimer)",
          "type": "OTHER"
        },
        {
          "name": "Continue on anticoagulant therapy (positive d-dimer)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "McMaster University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 410,
      "start_date": "2008-09",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-13",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720915"
    },
    {
      "nct_id": "NCT05064540",
      "title": "JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "AAA",
        "AAA - Abdominal Aortic Aneurysm"
      ],
      "interventions": [
        {
          "name": "Alto Abdominal Stent Graft System",
          "type": "DEVICE"
        },
        {
          "name": "FDA Approved EVAR AAA Graft Systems",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Endologix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2021-09-20",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 29,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064540"
    },
    {
      "nct_id": "NCT02925000",
      "title": "Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "TLC178",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiwan Liposome Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2017-06-19",
      "completion_date": "2020-10-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • The Bronx, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925000"
    },
    {
      "nct_id": "NCT01468532",
      "title": "Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "pasireotide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2011-10",
      "completion_date": "2017-07-20",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01468532"
    },
    {
      "nct_id": "NCT03274687",
      "title": "Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage I Prostate Adenocarcinoma AJCC v7",
        "Stage II Prostate Adenocarcinoma AJCC v7",
        "Stage III Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 296,
      "start_date": "2017-07-28",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 229,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03274687"
    },
    {
      "nct_id": "NCT01253200",
      "title": "Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Flutter"
      ],
      "interventions": [
        {
          "name": "Blazer® Open-Irrigated Ablation Catheter",
          "type": "DEVICE"
        },
        {
          "name": "Control Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2011-01",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Fullerton, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253200"
    },
    {
      "nct_id": "NCT02607800",
      "title": "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF/VEL/VOX",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 943,
      "start_date": "2015-11-16",
      "completion_date": "2017-01-11",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-11-02T23:39:10.702Z",
      "location_count": 47,
      "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02607800"
    }
  ]
}